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Post-keratoplasty infectious keratitis (PKIK) represents a unique clinical entity that often
poses significant diagnostic and therapeutic challenges. It carries a high risk of serious
complications such as graft rejection and failure, and less commonly endophthalmitis.
Topical corticosteroids are often required to reduce the risk of graft rejection but their use
in PKIK may act as a double-edged sword, particularly in fungal infection. The increased
uptake in lamellar keratoplasty in the recent years has also led to complications such
as graft-host interface infectious keratitis (IIK), which is particularly difficult to manage.
The reported incidence of PKIK differs considerably across different countries, with a
higher incidence observed in developing countries (9.2–11.9%) than developed countries
(0.02–7.9%). Common risk factors for PKIK include the use of topical corticosteroids,
suture-related problems, ocular surface diseases and previous corneal infection. PKIK
after penetrating keratoplasty or (deep) anterior lamellar keratoplasty is most commonly
caused by ocular surface commensals, particularly Gramme-positive bacteria, whereas
PKIK after endothelial keratoplasty is usually caused by Candida spp. Empirical
broad-spectrum antimicrobial treatment is the mainstay of treatment for both PKIK,
though surgical interventions are required in medically refractory cases (during the acute
phase) and those affected by visually significant scarring (during the late phase). In
this paper, we aim to provide a comprehensive overview on PKIK, encompassing the
epidemiology, risk factors, causes, management and outcomes, and to propose a
treatment algorithm for systematically managing this challenging condition.
Keywords: corneal graft, corneal infection, corneal transplant, corneal ulcer, eye bank, interface infectious
keratitis, keratoplasty, steroid
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INTRODUCTION
Corneal opacity is the 5th leading cause of blindness globally,
with around 6 million of the population being affected (1–3).
Among all aetiologies, infectious keratitis (IK), also known as
microbial keratitis or infectious corneal ulceration, consistently
features as the most common culprit of corneal blindness,
particularly in the developing countries. IK is a painful
and potentially blinding condition that may require hospital
admission for intensive medical treatment and/or surgical
interventions (1, 2). It can be caused by a wide array of organisms,
including bacteria, fungi, viruses, parasites or mixed infection
(1, 4, 5). Nonetheless, as the ocular surface is equipped with
a multifaceted defence system (6, 7), IK rarely occurs in the
absence of any predisposing factor. Commonly reported risk
factors include contact lens wear, trauma, ocular surface disease
and ocular surgery, particularly keratoplasty (1, 2, 8, 9).
Post-keratoplasty infectious keratitis (PKIK) represents a
challenging clinical entity that often poses significant diagnostic
and therapeutic challenges. It is uniquely different from a
“standard” IK in several ways. Firstly, the occurrence of IK in
a graft can result in potentially devastating complications such
as graft rejection, failure and endophthalmitis (10–12). Secondly,
topical corticosteroids are often required to reduce the risk
of graft rejection. However, in the event of PKIK, the use of
topical corticosteroids may act as a double-edged sword as it
can worsen the infection during the acute phase, particularly in
fungal infection. Furthermore, there has been a paradigm shift
in keratoplasty in the past decade where lamellar keratoplasty
such as deep anterior lamellar keratoplasty (DALK), Descemet
stripping automated endothelial keratoplasty (DSAEK), pre-
Descemet’s endothelial keratoplasty (PDEK), and Descemet
membrane endothelial keratoplasty (DMEK) have superseded
penetrating keratoplasty (PKP) as the preferred choice of
keratoplasty for anterior and posterior corneal pathologies (13–
19). However, this has also resulted in a number of complications
that are not usually observed following PKP, including graft
detachment and interface infectious keratitis (IIK) (20–23). IIK,
a unique subtype of PKIK which can develop after ALK or
EK, is a difficult-to-treat condition as the sequestration of the
infective microorganisms at the graft-host interface hinders
access for obtaining samples for microbiological culture and for
topical antimicrobial treatment to effectively reach and treat the
affected site.
As corneal transplant is the most commonly performed type
of transplant worldwide, the occurrence of PKIK and its resultant
complications have a significant impact. In this paper, we aim to
provide a comprehensive overview on PKIK, encompassing the
epidemiology, risk factors, causes, management and outcomes,
and to propose a treatment algorithm for systematically
managing this challenging condition.
METHOD OF LITERATURE SEARCH
We searched PubMed (January 1980–2021) for relevant articles
related to IK after keratoplasty. Keywords such as “infectious
keratitis,” “corneal ulcer,” “corneal infection,n, “microbial
keratitis,” “keratoplasty,” “corneal transplantation,” and “corneal
graft” were used. Only articles published in English were
included for the review. The search was first performed on 10
September 2020 and was last updated on 05 January 2021. The
literature search retrieved 328 articles, of which the abstracts
and titles were screened for those that fulfilled the eligibility
criteria. After excluding ineligible studies, 48 were included
in the qualitative synthesis. A PRISMA flow chart is provided
in Supplementary Figure 1. The demographic factors, clinical
characteristics and outcomes of PKIK of large case series (>500
cases) are summarised in Table 1.
EPIDEMIOLOGY
Incidence/Prevalence
The incidence of PKIK differs considerably across different
countries, with a higher incidence observed in developing
countries than developed countries. Depending on the study
design, patient cohort and follow-up duration, the incidence of
PKIK in developed countries ranges from 0.02 to 7.9% (Table 1)
(26, 28, 29, 31, 33, 36–44). The incidence of PKIK in developing
countries is less well documented within the literature, with a
higher overall incidence of up to 9.2–11.9% (35, 45). The higher
incidence may be attributable to the reduced access to healthcare,
poor follow-up compliance, lower level of education, increased
risk due to trauma and poor hygiene, poverty and a higher
proportion of primary keratoplasty performed as therapeutic
keratoplasty for IK (35, 45).
Age
PKIK affects patients of all age groups, with the majority of
cases reported in the literature being between the range of 17–
95 years (12, 26, 28, 33, 34, 36, 46–50). This reflects the varied
indications for keratoplasty such as keratoconus, pseudophakic
bullous keratopathy, Fuchs endothelial dystrophy and corneal
ulceration, scarring, or perforation within the adult population
(12, 51). In comparison, the main indications for keratoplasty
within the paediatric population include keratoconus, regraft,
and herpes simplex keratitis (HSK), with a higher preponderance
of congenital conditions such as anterior segment dysgenesis
(including Peter’s anomaly), congenital hereditary endothelial
dystrophy and sclerocornea, amongst others (52–54). A study in
Denmark evaluated keratoplasties performed in children under
16 over a 40-year period and found that infection was responsible
for 20% of failed grafts (55). In a longitudinal retrospective study
of 168 paediatric eyes in India, PKIK occurred in 29% of eyes and
was responsible for 50% of failed grafts (45). However, the most
common indication for keratoplasty in this study was infectious
keratitis (43%), which was associated with a high recurrence
rate (56).
Gender
There does not appear to be a gender predilection amongst
PKIK. Studies conducted in the Taiwan (51–60%) and Turkey
(57%) have found a marginally higher preponderance amongst
males (10, 28, 48), whereas a slightly higher preponderance in
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PK, Penetrating keratoplasty; EK, Endothelial keratoplasty; DALK, Deep anterior lamellar keratoplasty; CL, Contact lens; SR, Suture-related problems; GF, Graft failure; PED, Persistent
epithelial defect; HSV, Herpes simplex virus; TS, Topical steroids; TG, Glaucoma drops.
females was seen in the United States (56–60%) and Korea (57%)
(31, 47, 50).
Socioeconomic Status, Level of Education,
and Occupation
Patients from rural regions with lower socioeconomic status
and lower levels of education have reduced access to healthcare
and are less likely to attend follow-up appointments following
keratoplasty. This is reflected within a study conducted in India
whereby 75% of patients were from rural communities, with a
high rate (28%) of PKIK being observed (45). Additionally, a
China study reported farmers to be a significant independent
risk factor of PKIK due to higher risk of trauma, particularly
from plants resulting in fungal keratitis (57). These populations
also have a higher risk for non-compliance of post-operative
medication administration and hygiene (58).
Influence of the Types of Keratoplasty
The types of keratoplasty, including PKP, DALK and EK,
have also been shown to greatly influence the incidence, risk
and types of PKIK (i.e. ocular surface-related infection or
IIK). A large retrospective cohort study of 2,098 keratoplasty
performed between 2007 and 2018 in the US observed a
PKIK incidence of 5.9% and 1.3% following PKP and EK,
respectively (24). The higher proportion of PKIK occurring
in PKP (93%) compared to DALK (6%) and EK (0%) was
similarly depicted in a UK study of 1,508 grafts (25). The higher
proportion of PKIK after PKP hinges on a combination of factors,
including the indication for surgery, the use of sutures, and
the prolonged use of topical corticosteroids. The indications
for EK tend to be non-infective causes such as endothelial
dystrophy, whereas a wider range of ocular comorbidities
indicated for PKP may include IK and repeat (high-risk) grafts
(24). Additionally, the requirement for corneal sutures in PKP,
compared to EK, poses substantial risk of IK. This however
does not completely explain the difference between PKP and
DALK, with both procedures requiring the same number of
sutures, though DALK usually does not require long-term
topical corticosteroids due to zero-risk of endothelial graft
rejection (59).
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Conversely, a retrospective study using data from the Eye
Bank Association of America analysing all adverse events of
corneal grafts found a higher proportion of PKIK in EK (67%)
compared to PKP (29%) and ALK (3%) (29). However, it is
important to note that this study only included cases of PKIK
that were caused by graft-transmitted infection. In addition,
when taking into account the total number of each procedure
performed (PKP/ALK/EK), the incidence of graft-transmitted
infection was similar between EK and ALK (both 2.6 cases
per 10,000 grafts) but higher than PKP (0.9 per 10,000 grafts).
Interestingly, a higher rate of fungal infection was observed
when compared to non-US studies, possibly related to the lack
of antifungal agent in the corneal storage medium in the US.
(11, 29). The authors also noted a 1.5–3 times higher risk of
fungal infection following EK (compared to ALK and PKP),
potentially related to the increased warming time associated with
the preparation of EK tissues in the eye bank (29).
RISK FACTORS
Topical Corticosteroids
Topical corticosteroids are usually administered following
keratoplasty to reduce the risk of graft rejection (60). As such,
the majority of studies have found topical corticosteroids to be
the main contributing factor (72.2–100%) for PKIK, primarily
attributed to its local immunosuppressive effect (12, 25, 32–
34, 41, 42, 47, 50) (Figure 1A). A US study observed that 82.6%
eyes that developed PKIK were on topical corticosteroid therapy,
of which the rates between PKP and EK were comparative at 81.3
and 90.9%, respectively (24). Constantinou et al. (30) performed
a retrospective study evaluating non-suture-related PKIK after
PKP between 1998 and 2008 in Australia. Long-term topical
corticosteroids use was noted in 88% of eyes with PKIK, with 61%
eyes developed infection more than 2 years after PKP. Similarly,
a UK study (25) observed 89% of their patients developed PKIK
(after PKP or DALK) whilst on topical corticosteroids, with a
median time of developing IK at 25 months post-keratoplasty
(25). This is an interesting observation as one would expect
PKIK to develop sooner if the use of topical corticosteroids
is directly implicated in the pathogenesis of PKIK since it is
often used at a higher frequency and dose during the early
postoperative period. Plausible explanations for late occurrence
of PKIK include the occurrence of loose or broken sutures, the
development or exacerbation of ocular surface diseases such as
dry eyes and neurotrophic keratopathy (with persistent epithelial
defect), and graft failure with resultant bullous keratopathy (25,
30). In addition, while many studies reported the association of
PKIK and use of topical corticosteroids, they did not examine the
proportion of grafts that did not develop PKIK while on topical
corticosteroids. Future studies examining the incidence of PKIK
in all corneal grafts while on topical corticosteroids (including
those that did not develop PKIK) would be of clinical interest.
Suture-Related Problems
Suture-related problems are a major risk factor for IK and
has been implicated in 20–50% cases of PKIK, mainly after
PKP and DALK (12, 34, 42, 61, 62) (Figure 1B). Furthermore,
FIGURE 1 | Examples of post-keratoplasty infectious keratitis (PKIK). (A) A
case of PKIK caused by Streptococcus pneumonia in an eye after Descemet
membrane endothelial keratoplasty, while on topical corticosteroids. (B) A
case of suture-related PKIK caused by Staphylococcus aureus in an eye after
penetrating keratoplasty. (C,D) A case of PKIK caused by Pseudomonas
aeruginosa in an eye with failed Descemet stripping automated endothelial
keratoplasty with bullous keratopathy, while on topical steroids. (C)
demonstrates the presence of decompensated corneal graft prior to the
infection. (E,F) A case of PKIK caused by Moraxella catarrhalis in an eye with
failed penetrating keratoplasty with bullous keratopathy, while on topical
steroids.
suture complications increase the risk of graft rejection and
failure (42, 63). The occurrence rate of PKIK caused by loose
or broken sutures is reported to be as high as 71.6% (10, 12,
25, 26, 28, 36, 39, 43, 49). Four main causes of suture loosening
have been described, which include corneal deturgescence,
incomplete epithelialisation over the suture material, suture
degradation (exacerbated by corneal vascularisation around the
sutures), and cheese-wiring (39). The broken or loose suture
is implicated in PKIK by causing a resultant epithelial defect
that can be contaminated by environmental and ocular surface
commensals (39). Cheese-wiring is seen particularly in corneas
with keratoconus whereby little support is offered by the thin
host cornea (39). In addition, patients with keratoconus are often
affected by atopic disease, which increases the postoperative risk
of corneal vascularisation around the graft sutures, loose/broken
sutures, and graft failure (64). A greater propensity for suture-
related infections seems to occur within the interpalpebral
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zone, likely due to the increased risk of exposure and reduced
protection of the eyelids (34, 42).
Suture-related problems generally occur either within 1 year
or around 30 months following keratoplasty (37, 39, 42, 63, 65,
66). The reason for the bimodal peak noted in these studies
may be due in part to the process of suture-loosening and
surgeons’ preference as somemay remove all corneal graft sutures
at 12–18 months post-keratoplasty. Corneal deturgescence and
incomplete epithelialization over the suture may result in an
earlier onset of infection, whereas suture degradation and cheese-
wiring of the corneal tissue contribute to a later onset (39, 42).
Christo et al. advocated the removal of sutures as soon as
the graft-wound interface is healed at 1 year for vascularised
recipients and 18 months for all other cases to minimise the
risk of suture-related PKIK, with earlier removal in children
(39, 67). However, individualised care is necessary due to variable
speed in wound healing (e.g., slower in elderly patients) whereby
wound dehiscence or large changes in keratometry can occur
upon premature suture-removal (39, 68).
Previous History of IK
Keratoplasty serves as a useful therapeutic modality in managing
patients with IK. It can be performed in the form of optical
keratoplasty for visual rehabilitation (by removing the corneal
scar) or in the form of therapeutic keratoplasty to manage active,
medically refractory IK (15, 69). However, the occurrence of
PKIK following therapeutic keratoplasty is high (6–41%) and the
risk may be influenced by the type of previous infection (56, 70–
72). Wagoner et al. (12) observed 18.6% of those that developed
bacterial PKIK were associated with a history of previous
bacterial keratitis. Fungal recurrence rates are variable with a
range of 7.4–32.7%, with most recurrences presenting within 2
weeks of surgery (73, 74). Due to the propensity of fungi for deep-
seated infections with corneal penetration and anterior chamber
invasion, the final outcomes of graft clarity (51–84%) and final
cure rate requiring no further regrafts (69–90%) are reduced
in comparison to a recurrence of bacterial keratitis (69–90%
and 90–100%, respectively) (73–76). Therapeutic keratoplasty
performed for refractory Acanthamoeba keratitis (AK) is often
unsuccessful in elimination of the infection, necessitating
repeat grafts with resultant guarded outcome (71). In addition,
recurrence of HSK post-keratoplasty is common, with ∼50%
seen within the first 2 years following PKP and in 33% at 3
years for DALK, and is usually associated with a high risk of
graft rejection and failure (77–79). However, it is noteworthy
to mention that most of these studies were conducted more
than 1–2 decades ago. Recognition of the high recurrent risk of
HSK had led to increased use of prophylactic oral aciclovir post-
keratoplasty, which could reduce the risk of HSK recurrence and
resultant graft rejection/failure (80).
Ocular Surface Diseases
Ocular surface diseases constitute a significant risk factor for
PKIK (following PKP and DALK) due to the poor ocular
environment, breakdown of corneal epithelium, and reduced
tear film quantity and quality (including its antimicrobial
compounds) (81). Causes include dry eye disease (22.2–
28.2%), blepharitis (23.8–43.6%), persistent epithelial defect or
neurotrophic keratopathy (14.3–77.8%), trichiasis (13.3–39%),
and exposure keratopathy (10, 28, 31, 33, 35, 36, 43, 47–49, 62).
In addition, the corneal sensation may only return to a normal
level after 12 months post-PKP and DALK, and in some cases
never fully recover, which renders the cornea more susceptible to
epithelial breakdown and infection (82). It is also worth noting
that bullous keratopathy secondary to graft failure, following
any type of keratoplasty, serves as another important risk factor
(6–61%) for PKIK (Figures 1C–F).
Cornea Preservation Method
Currently, two main methods are used to store and preserve
donor corneas in the eye banks, including organ culture and
hypothermia (83). Organ culture involves suspending corneal
tissues in cell culture medium (most commonly Eagle’s minimum
essential medium) with foetal bovine serum. Antibiotics and
antifungals are added to prevent growth of microorganisms
(83). Additionally, frequent testing of the suspension medium
for microbial growth is conducted to ensure the sterility before
transplantation. This method is able to preserve corneas for up to
4 weeks at 28–37◦C (83). On the other hand, the hypothermia
method utilises storage medium such as Optisol-GS (which
contains dextran and chondroitin sulphate) to prevent corneal
oedema and is able to preserve corneas for 7–14 days at a
temperature of 2–8◦C (83). While presenting a clear advantage
of its technical simplicity, the lower storage temperature and
shorter storage duration may reduce the chance of microbial
detection before transplantation, thereby increasing the risk of
PKIK (84, 85).
Hypothermic storage has been shown to have a higher
positive rim culture rate (9.8%) compared to organ culture
(1.3%) (84). Similarly, a Spanish study observed a 3.2% positive
microbiological culture among 1,369 donor corneoscleral rims
and found that 61.8% were related to corneas stored in
hypothermia (86). Notably, the preferred hypothermic storage
medium used in Europe and US contains only antibiotics (e.g.,
gentamicin) but without an antifungal agent as seen in the organ
culture medium (29, 85). This may explain the higher rates of
PKIK due to Candida spp. following EK utilising hypothermic-
stored corneas at European and US centres (29, 85). It is also
worth noting that subsequent postoperative fungal infection is
seen in 7% of the corneas with positive donor rim fungal culture
(87). In view of these issues, addition of antifungal agent into
the hypothermic storage medium has been proposed (88, 89).
However, further investigations into the efficacy, safety and
choice of antifungal agent are required as the microbiological
profiles may be highly varied across different regions and




Bacteria form the largest cohort of microorganisms responsible
for PKIK worldwide. Although both Gramme-positive and
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Gramme-negative bacteria are implicated, the literature
consistently highlights Gramme-positive bacteria as the most
common type of organism, with up to 82.8% reported in some
studies (12, 25, 26, 32–36, 39, 41–43, 45, 47, 48, 50). These
Gramme-positive bacteria, which constitute the ocular surface
commensals, include Staphylococcus aureus, closely followed by
Streptococcus pneumoniae and coagulase-negative Staphylococcus
such as Staphylococcus epidermidis (10, 12, 25–29, 32–36, 39, 41–
43, 45, 47–50). Of interest, this pattern has remained the same
over the last four decades. However, variable and non-stringent
culture protocols across different regions could considerably
impact the range of organisms reported (90).
Fungi
The most common fungus associated with PKIK, particularly
EK, are from the Candida species, with the majority caused by
either Candida albicans or Candida parapsilosis (10, 25, 29, 33,
34, 43, 47, 48, 50, 89, 91–94). The other less commonly reported
fungi implicated in PKIK include Fusarium spp. and Aspergillus
spp., as well as rare organisms such as Cryptococcus spp. and
Arthrographis spp. (28, 34, 49, 50, 95, 96).
Viruses
Herpes simplex keratitis (HSK) represents an important cause
for PKIK. Although accounting for <7% of microbial causes
of PKIK (29, 35), the incidence calculated by a Dutch study of
2,112 patients is 1.2 per 1,000 person-years (97). Comparatively,
a Chinese study of 1,443 patients found the incidence to be
1.2% (98). Post-keratoplasty HSK can present as classic dendritic
keratitis, geographic ulcer, or non-healing epithelial defect (97).
Interestingly, HSK may develop following keratoplasty despite
no previous diagnosis, with the majority presenting within 2
years of transplantation (97). This is likely to be attributable
to the high seropositive rate within the population despite
being asymptomatic and the suppression of local immunity with
corticosteroids use (98, 99). As such, HSV should be considered
as a diagnosis in cases of non-resolving epithelial defects
following keratoplasty. Cytomegalovirus (CMV) infection is
another important cause of graft infection, rejection and failure
following PKP and EK, though it is most commonly reported
in East Asia (100, 101). A recent UK study failed to identify the
presence of CMV in any of the 92 cases of failed corneal graft
tissues, suggesting that CMV may be a region-specific risk factor
for graft infection and failure (102).
Others
Apart from recurrences following therapeutic keratoplasty,
other types of IK, secondary to Acanthamoeba and acid-fast
bacillus (e.g., non-tuberculousMycobacterium), have rarely been
reported after keratoplasty (12, 33, 103).
DIAGNOSIS
Microscopy, Culture, and Sensitivity
The diagnostic approach for PKIK is similar to “standard”
IK, unless the PKIK is related to IIK. Corneal scraping
for microscopy, culture and sensitivity testing represents the
gold standard for diagnosing IK, though the culture yield
varies between 24 and 77% (1, 2, 104, 105). To maximise
collection of microorganisms for culture, the corneal scrape
should be taken at the ulcer base or leading edge. Microscopic
examination with appropriate staining (e.g., Gramme stain,
Giemsa stain, potassium hydroxide with calcofluor white) serves
as a more rapid diagnostic method of IK (106). Various agars
are used for culturing the causative microorganisms, including
blood/chocolate agar (for bacteria), Sabouraud dextrose agar
(for fungi), and non-nutrient agar with Escherichia coli overlay
(for Acanthamoeba).
In suture-related PKIK cases, infected corneal sutures should
also be sent for microbiological culture as they may provide
additional information. Adler et al. (107) evaluated the presence
of microbial growth and biofilm formation amongst corneal
sutures removed following astigmatic correction (quiescent),
loosening or breakage (exposed), or infection. Biofilms are
composed of extracellular matrix secreted by microorganisms
and are usually resistant to conventional antimicrobial treatment
(108, 109). They have been shown to form on biotic and
abiotic surfaces, including sutures (107, 110). In their study,
the infection group demonstrated a culture yield of 60%
based on corneal sutures, underlining corneal suture material
(when infected) as a useful source for obtaining microbiological
diagnosis. In addition, higher biofilm scores (on scanning
electron microscopy) were observed in the infection and exposed
groups, highlighting the importance of early removal of sutures
to prevent suture-related PKIK.
In vivo Confocal Microscopy
In vivo confocal microscopy (IVCM) is a non-invasive diagnostic
investigation allowing visualisation of the cornea at high
resolutions of 1–2µm by limiting scattered light and focusing
the observation system to a single point (111). As such, it
offers a useful tool for determining fungal keratitis and AK
(but not bacterial keratitis). IVCM has the benefit of providing
rapid diagnoses but the diagnostic accuracy is reliant on the
operator’s experience (112). Compared to culture, IVCM is
able to detect fungal filaments with a sensitivity of 85.7–94%
and a specificity of 78–81.4% (113, 114). Similarly for AK,
the sensitivity and specificity are 88.2–100 and 98.2–100%,
respectively (113, 115, 116). Additionally, IVCM lends itself as an
important investigation for determining the causes of IIK where
access for corneal sampling is limited (22, 117). Recently, artificial
intelligence (AI)-assisted diagnosis based on IVCM images has
been shown to reliably diagnose fungal keratitis (118, 119).
Anterior Segment Optical Coherence
Tomography
AS-OCT utilises low-coherence interferometry to provide high-
resolution, cross-sectional imaging of the cornea (120). As AS-
OCT can provide a quantitative and objective measurement of
the infection, it can be used to observe characteristic patterns
of IK, determine the depth and extent of IK, and monitor
the progression of IK and treatment response, especially in
deep-seated infection or IIK (Figure 2) (121–124). In addition,
it is of particular importance in fungal keratitis as fungi
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FIGURE 2 | A case of interface infectious keratitis (IIK) following Descemet
stripping automated endothelial keratoplasty (DSAEK). (A,B) Slit-lamp
photography demonstrating an inflamed right eye with diffused stromal haze in
a crisscross pattern at the graft-host interface (blue arrows), consistent with a
diagnosis of IIK. The edge of the DSAEK graft is visible (yellow arrow). The
hyper-reflective changes at the graft-host interface (red arrows) are clearly
delineated on anterior segment optical coherence tomography (AS-OCT)
highlighting the value of AS-OCT in facilitating the assessment of infectious,
keratitis. (C,D) Slit-lamp photography demonstrating a complete resolution of
the IIK following intensive topical anti-fungal treatment, evidenced by the
disappearance of the stromal haze on slit-lamp photograph and the
hyper-reflective changes at the graft-host interface on AS-OCT. (A) is
reproduced from Ting et al. (22) with permission.
have a propensity for deep-seated infection (which is more
difficult to visualise on slit-lamp examination/photography) and
a prolonged clinical course (125, 126).
TREATMENT
The treatment strategy is guided by a number of factors,
including the type of microorganism, severity, location, type
of keratoplasty, and clinicians’ experience and preference. A
proposed systematic treatment algorithm of PKIK is illustrated
in Figure 3.
Medical Treatment
Empirical broad-spectrum antimicrobial agents are the mainstay
of treatment for PKIK following both PKP and LK. Commonly
used topical antibiotics include fluoroquinolones and fortified
cephalosporins and aminoglycosides. Depending on the type
of fungal infection (filamentous vs. yeast), antifungal treatment
such as natamycin, amphotericin B, and voriconazole are
commonly administered. Early concurrent systemic antifungal
treatment is often initiated in severe cases (127, 128). Subsequent
medical treatment is then tailored to the clinical progress and
microbiological results. Akova et al. (36) reported successful
medical management in 43% eyes of the 21 eyes with IK following
PKP. Vajpayee et al. (62) observed a success rate of 74% in
resolving PKIK with medical management alone. In the event
where the use of topical steroids is contraindicated in grafted
patients (e.g., infection or steroid responder), topical ciclosporin
may serve as a useful substitute (129, 130).
IIK frequently poses a significant therapeutic challenge due
to the deep location of the infective nidus and entrapment
of organisms in the interface between host and donor tissues
(Figure 4) (21, 22, 91). Topical medications often have limited
penetration to the deep cornea and fail to reach a therapeutic
concentration at the site of infection. Epithelial debridement may
improve drug penetration. Although uncommon, the interface
infection may be heralded by an ocular surface infection or
may extend from the interface to the ocular surface, both of
which allow for scraping for microbiological culture and better
penetration of topical treatment (22, 131). However, medical
treatment alone has been shown to achieve successful eradication
of infection in only 13.3–24.2% cases of IIK, with high proportion
requiring surgical interventions (21, 91, 117, 132).
Intrastromal injections or interface irrigation with
antimicrobial agents may be used when the infection is not
responding to topical treatment, particularly in deep-seated
infection and IIK (Figure 4) (127, 132–134). Kalaiselvi et al.
(135) demonstrated that intrastromal voriconazole injection
was able to resolve 72% of deep recalcitrant fungal keratitis that
did not respond to topical natamycin and natamycin drops. Tu
and Hou (134) reported successful resolution of two cases of
post-DSAEK fungal IIK with repeated intrastromal antifungal
injection, obviating the need for PKP. However, it is important to
bear in mind that excessive injection of treatment extending into
the interface may weaken the graft-host attachment and risk graft
detachment and endophthalmitis (91, 127, 134). In addition,
a recent review showed that only 10% of the reported cases of
post-DSAEK IIK resolved without any surgical intervention,
highlighting the therapeutic challenge of this clinical entity (91).
Interface irrigation with antibacterial agents such as vancomycin
(5%) has reportedly been effective in clearing DALK-related
IIK (132). Use of antifungal agents such as amphotericin B
(0.15–0.5%), voriconazole (1.0–5.0%), and fluconazole (5%) have
also been described (91, 133, 136, 137). Apart from treatment,
Wessel et al. (133) have suggested using the irrigation fluid
obtained after interface wash for microbiological investigations.
Although rare, risk of Descemet membrane (DM) perforation
needs to be kept in mind in these cases (128, 138, 139).
Surgical Treatment
The choice of surgical treatment of PKIK is dependent on the
extent of infection and types of primary keratoplasty. In cases
of IK following PKP, therapeutic PKP is needed in large ulcers
not responding to medical treatment whereas optical PKP can be
performed at a later stage to remove significant IK scarring and
improve vision (140). Studies have reported that an emergency
TPK was required in ∼15–20% cases of severe PKIK and some
(up to 10%) may even require evisceration if it progresses to
endophthalmitis (36, 62).
In cases with ALK, the choice of surgical treatment depends
on the primary procedure. In cases where adequate host stroma
is left behind in the primary procedure, such as in manual
or automated ALK, the lamellar graft can be removed and
the surface allowed to re-epithelialise whilst on antimicrobial
treatment (141, 142). This helps reduce the microbial load
and facilitate the corneal healing (143). Once the infection has
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FIGURE 3 | A proposed systematic treatment algorithm of post-keratoplasty infectious keratitis (PKIK). *The proposed surgical approach is related to the
management of graft-host interface infectious keratitis. **Some may also consider removal of the donor lenticule + intracameral antimicrobial treatment.
healed, secondary DALK may be considered (144–146). In cases
where the primary procedure was DALK, the interface is more
likely to provide a potential space for sequestration of infection
resulting in recurrences later (147). Although clear grafts have
been achieved in repeat DALK procedures following IIK post-
DALK (136, 148), recurrences of infections have been reported
with cases then requiring PKP (147, 149). Emergency therapeutic
PKPmay be required in cases with non-responding infiltrates and
impending/actual perforations (139, 147).
In cases of DSAEK, removal of donor lenticule may lead
to intraocular spread of infection resulting in endophthalmitis
(21). However, in the presence of concomitant endophthalmitis,
removal of the donor lenticule helps by reducing the microbial
load and aids faster resolution (150). As such, removal of
donor lenticule is not recommended unless there is concomitant
endophthalmitis. A repeat DSAEK can be considered once
complete resolution of infection is achieved and if host cornea
is clear (151). In medically refractory IIK post-DSAEK, an
early excisional PKP (including the removal of the infected
DSAEK) is advisable as it helps remove the interface infection
and prevents intraocular spread of infection and subsequent
endophthalmitis (152). Few cases of IIK have been reported
after DMEK. Thompson et al. (153) reported a case of fungal
keratitis and endophthalmitis post-DMEK. The authors removed
the DMEK graft and administered intravitreal antifungal agents
every alternate day until the infection resolved. DSAEK was
then performed as a secondary procedure, which achieved a
final best-corrected-visual-acuity (BCVA) of 6/18. Another case
of post-DMEK interface fungal keratitis with endophthalmitis
was reported by Doshi et al. (154). Initial conservative treatment
with intracameral and intravitreal antifungals did not result in
improvement. The patient was then subjected to pars plana
vitrectomy and 3mmof central plaque was removed fromDMEK
graft using a vitrector. Oral treatment with posaconazole was
started and complete eradication of infection was observed at
2-month follow-up.
In the recent years, there has been an increasing popularity
in the use of therapeutic corneal cross-linking (PACK-CXL)
for treating bacterial and fungal keratitis, particularly in
recalcitrant cases (155–157). Mikropoulos et al. (158) described
an innovative use of PACK-CXL in managing a case of PKIK
secondary to multidrug resistant fungal keratitis. PACK-CXL was
applied to the infected graft and the affected corneoscleral rim
intraoperatively followed by a same-day therapeutic keratoplasty.
The graft remained free of infection during the 9-month follow-
up. However, larger case series are required to examine the
efficacy and safety of such approach.
OUTCOME
Following treatment of PKIK, a clear graft was seen in 23–81% of
eyes (10, 26, 28, 31–33, 36, 42, 43, 47–50). However, regrafts were
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FIGURE 4 | A case of right recurrent interface infectious keratitis (IIK) after
deep anterior lamellar keratoplasty (using manual dissection technique) for
keratoconus. (A,B) Slit-lamp photography in Aug 2018 demonstrating a
suture-related infection, with a mid-stromal infiltrate and a small overlying
epithelial defect along the suture track at 7 o’clock (red arrows), with
surrounding stromal oedema/folds. The infected broken suture was removed,
and the infection was successfully resolved with topical antibiotic treatment.
(C,D) A year later, slit-lamp photography showing a recurrent mid-to-deep
stromal infiltrate (involving the graft-host interface) at the same site with inferior
corneal graft vascularization, suggesting an atypical presentation of IIK. The
recurrence was likely due to a “reactivation” of the previously treated infective
nidus at the graft-host interface. (E) Improvement of the superficial infection
was observed after two weeks of intensive antibiotic treatment. The residual
IIK (yellow arrow) was resolved after a further 3 weeks of topical antibiotic
treatment. (F) Further recurrence of infection was again observed in October
2020. Note the gradual migration of the infection towards the visual axis along
the graft-host interface, compared to the previous years. (G) The patient was
treated for a mixed bacterial/fungal infection with intensive topical antibiotic
and antifungal treatment, but only a partial response was observed. A course
of repeated intrastromal injections of voriconazole 0.1% (0.1ml) was
subsequently given every weekly for 4 weeks. (H) Complete resolution of
infection was achieved, with a residual scar.
performed in 4.5–53% of cases (25, 33, 34, 36, 42, 47, 49). The
visual outcome varied among studies, with only 20.6–56% of eyes
achieving a final BCVA of≥6/60 (12, 28, 48). Wagoner et al. (12)
found that whilst 59.8% had ambulatory vision (counting fingers
or better), only 7.8% had a BCVA of ≥6/12 after recovering
from PKIK. Interestingly, extreme of age (either <12 or >60
years) was a poor prognostic factors for visual outcome (12).
In a study with patients who received therapeutic PKP to treat
medically-uncontrolled IK, a clear graft was sustained in 47.4%
eyes at 2 years post-graft, with a mean BCVA of 1.8 logMAR
(56). The authors proposed that these relatively poor outcomes
were likely due to a combination of late surgical treatment,
increased virulence of microorganisms, recurrence of infection,
and reduced response to antimicrobials. As such, timely detection
and management of PKIK could lead to better outcomes (56).
COMPLICATIONS
A number of complications have been documented in the
literature following PKIK, including graft rejection, failure, and
endophthalmitis requiring evisceration/enucleation (25, 33, 42,
43, 48, 96, 159). Graft rejection and/or failure was found to
occur in 7.3–71.4% cases (10, 12, 25, 26, 28, 43, 45, 49).
In particular, older grafts were more likely to fail following
PKIK (26). Endophthalmitis occurred in 1–13% of cases, with
a large proportion of cases requiring either evisceration (75–
100%) or regraft for visual rehabilitation (25%) (25, 28, 33–
35, 49). Chen et al. (11) demonstrated that cause of death
secondary to infection, high risk indication (i.e., infection, injury,
and ulcerative keratitis), and therapeutic grafts increased the
risk of endophthalmitis following penetrating keratoplasty. In
addition, the time to onset of endophthalmitis may provide
a useful clue to the causative organisms as bacterial infection
was shown to occur significantly earlier than fungal infection (a
median time of 2.5 vs. 33 days post-keratoplasty) (29). Additional
complications of PKIK include corneal perforation (4.9–35%),
infectious crystalline keratopathy (6%), orbital cellulitis (1%),
corneal scarring (17–36%), persistent epithelial defect (39%),
corneal neovascularisation (15%), wound dehiscence (11.9–
35%), and phthisis bulbi (9%) (25, 26, 28, 32–35, 39, 42, 47, 49,
50, 159).
CONCLUSION
PKIK is a clinical entity that often poses significant diagnostic
and therapeutic challenges. It carries a high risk of serious
complications such as graft rejection and failure, and less
commonly endophthalmitis. PKIK after PKP and ALK is most
commonly caused by ocular surface commensals, particularly
Gramme-positive bacteria, whereas PKIK after EK is usually
caused by Candida spp. Broken or loose sutures have been
consistently shown to be main risk factor of PKIK and early
suture removal is advocated whenever clinically possible. With
the increased adoption of EK in the recent years, it is likely
that the incidence of PKIK will reduce. Optimal management
of ocular surface diseases such as dry eye, blepharitis, exposure
keratopathy, and neurotrophic keratopathy will help reduce
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the risk of PKIK following PKP and DALK. Refinement in
the preservation method (e.g., addition of antifungal agent in
hypothermic method) may reduce the risk of graft-transmitted
infection, particularly in EK. However, further investigations
into the efficacy and the choice of antifungal agent are
required as the microbiological profiles may be highly varied
across different regions. A stepwise treatment strategy can
often be used to successfully treat PKIK, though IIK often
requires surgical interventions to achieve complete resolution
of the infection.
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